3 active not recruiting. 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 2 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow ABBV-RGX-314 Dose 1: new trials by email Literature Review of ABBV-RGX-314 Dose 1 trials Research Report on ABBV-RGX-314 Dose 1
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, Aflibercept (EYLEA®) - AMD, nAMD | Phase 3 | Active not recruiting | AbbVie | 735 | 2022-01-13 | 2026-08-03 |
| RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME) ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, ABBV-RGX-314 Dose 3 - Diabetic Retinopathy (DR), Center-Involved Diabetic Macular Edema (CI-DME) | Phase 2 | Active not recruiting | AbbVie | 139 | 2020-11-20 | 2026-08-19 |
| RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) Ranibizumab, ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2 - Neovascular Age-Related Macular Degeneration (nAMD) | Phase 2 | Active not recruiting | AbbVie | 146 | 2020-08-25 | 2026-02-27 |
Choroidal Neovascularization (1) · Diabetic Retinopathy (1) · Eye Diseases (1) · Macular Degeneration (1) · Retinal Degeneration (1) · Retinal Diseases (1) · Wet Macular Degeneration (1)
AbbVie (3)
United States (3) · Canada (1) · France (1) · Germany (1) · Hungary (1) · Italy (1) · Japan (1) · Puerto Rico (1) · Spain (1) · United Kingdom (1)